PHAYM001: Preparation for professional practice



1

Maher, A.R.: Efficacy and Comparative Effectiveness of Atypical Antipsychotic Medications for Off-Label Uses in AdultsA Systematic Review and Meta-analysis. JAMA: The Journal of the American Medical Association. 306, (2011). https://doi.org/10.1001/jama.2011.1360.

2.

Clinical guidelines, CG42 - Issued: November 2006, http://guidance.nice.org.uk/CG42.

3.

TA217 Alzheimer's disease - donepezil, galantamine, rivastigmine and memantine: guidance (MS Word format), http://guidance.nice.org.uk/TA217/Guidance/doc/English.

4.

Exelon - Summary of Product Characteristics (SPC) - (eMC), https://www.medicines.org.uk/emc/search?q=Exelon+.

5.

Aricept Tablets - Summary of Product Characteristics (SPC) - (eMC), http://www.medicines.org.uk/emc/medicine/577/SPC/Aricept.

6.

Reminyl Tablets - Summary of Product Characteristics (SPC) - (eMC).

7.

Ebixa 5mg/pump actuation oral solution, 20mg and 10 mg Tablets and Treatment Initiation Pack - Summary of Product Characteristics (SPC) - (eMC), http://www.medicines.org.uk/EMC/medicine/10175/SPC/rEbxia+5mg+pump+oral+solution %252c+20mg+and+10+mg+tablets+and+Treatment+Initiation+Pack/.

8.

DH Living well with dementia: a National Dementia Strategy, https://www.gov.uk/government/organisations/department-of-health.

9.

British National Formulary, http://www.bnf.org/bnf/index.htm.

10.

Bhasin, M., Rowan, E., Edwards, K., McKeith, I.: Cholinesterase inhibitors in dementia with Lewy bodies—a comparative analysis. International Journal of Geriatric Psychiatry. 22, 890–895 (2007). https://doi.org/10.1002/gps.1759.

11.

Kavirajan, H., Schneider, L.S.: Efficacy and adverse effects of cholinesterase inhibitors and memantine in vascular dementia: a meta-analysis of randomised controlled trials. The Lancet Neurology. 6, 782–792 (2007). https://doi.org/10.1016/S1474-4422(07)70195-3.

12.

Warner, J., Smith, T.: The rise and fall of antipsychotic prescribing in dementia. Where do we go from here? The rise and fall of antipsychotic prescribing in dementia. 14, 24–27.

13.

Sube Banerjee: The use of antipsychotic medication for people with dementia: Time for

action. A report for the Minister of State for Care Services, http://psychrights.org/research/digest/nlps/BanerjeeReportOnGeriatricNeurolepticUse.pdf, (12)AD.

14.

Optimising treatment and care for behavioural and psychological symptoms of dementia: A best practice guide, https://www.alzheimers.org.uk/bpsdguide.

15.

Treatment protocol by NHS Medway: Treatment of Behaviour That Challenges, http://www.kmpt.nhs.uk/policies.

16.

Antipsychotics increase mortality in elderly patients with dementia, http://www.npc.nhs.uk/merec/cns/dementia/merec_extra_no39.php.

17.

Electronic Medicines Compendium (eMC), http://www.medicines.org.uk/emc/.

18.

Pierre N. Tariot, M.D.; Rosemary Erb, R.N., B.S.N.; Carol Ann Podgorski, Ph.D.; Christopher Cox, Ph.D.; Shirish Patel, M.D.; Laura Jakimovich, M.S., R.N.; Carrie Irvine, B.A.: Efficacy and Tolerability of Carbamazepine for Agitation and Aggression in Dementia. Psychiatry | Efficacy and Tolerability of Carbamazepine for Agitation and Aggression in Dementia. 155, 54–61 (1998). https://doi.org/10.1176/ajp.155.1.54.

19.

Martinón-Torres, G., Fioravanti, M., Grimley Evans, J.: Trazodone for agitation in dementia. Cochrane Database of Systematic Reviews. (2004). https://doi.org/10.1002/14651858.CD004990.

Electronic Medicines Compendium (eMC), http://www.medicines.org.uk/emc/.

21.

Risperdal Tablets, Liquid & Quicklet - Summary of Product Characteristics (SPC) - (eMC), http://www.medicines.org.uk/emc/document.aspx?documentid=12818&docType=SPC.

22.

Maher, A.R., Maglione, M., Bagley, S., Suttorp, M., Hu, J.-H., Ewing, B., Wang, Z., Timmer, M., Sultzer, D., Shekelle, P.G.: Efficacy and Comparative Effectiveness of Atypical Antipsychotic Medications for Off-Label Uses in Adults. JAMA. 306, (2011). https://doi.org/10.1001/jama.2011.1360.

23.

Complete Guide to Behavioural and Psychological symptoms of Dementia, http://www.ipa-online.org/.

24.

Waldemar, G., Hyvärinen, M., Josiassen, M.K., Kørner, A., Lehto, H., Wetterberg, P.: Tolerability of switching from donepezil to memantine treatment in patients with moderate to severe Alzheimer's disease. International Journal of Geriatric Psychiatry. 23, 979–981 (2008). https://doi.org/10.1002/gps.1979.

25.

Electronic Medicines Compendium (eMC), https://www.medicines.org.uk/emc/.

26.

Evidence Search - Search Engine for Evidence in Health and Social Care, https://www.evidence.nhs.uk/.

27.
Evidence Search - Search Engine for Evidence in Health and Social Care, https://www.evidence.nhs.uk/.
28.
Map of Medicine Home, http://www.mapofmedicine.com/.
29.
Medicines Information - Evidence Search - Search Engine for Evidence in Health and Social Care, https://www.evidence.nhs.uk/.
30.
NPC National Prescribing Centre, https://www.guidelinesinpractice.co.uk.
31.
National Institute for Health and Care Excellence, http://www.nice.org.uk/.
32.
NICE Clinical Knowledge Summaries (CKS), http://cks.nice.org.uk/.
33.
Scottish Intercollegiate Guidelines Network (SIGN), http://www.sign.ac.uk/.
34.

Centre for Medicines Optimisation - MTRAC | Independent Medicines Review | Midlands Therapeutics Review & Advisory Committee | Centre for Medicines Optimisation | Keele

University, http://centreformedicinesoptimisation.co.uk/mtrac/.

5/8

NPC | National Prescribing Centre, https://www.guidelinesinpractice.co.uk.

36.

Evidence Search - Search Engine for Evidence in Health and Social Care, https://www.evidence.nhs.uk/.

37.

GOV.UK, https://www.gov.uk/government/organisations/department-of-health.

38.

Miller, W.R., Rollnick, S.: Motivational interviewing: helping people change. Guilford Press, New York (2013).

39.

Prochaska, J.O., Norcross, J.C., DiClemente, C.C.: Changing for good. William Morrow, New York (1994).

40.

Rollnick, S., Mason, P., Butler, C.: Health behavior change: a guide for practitioners. Churchill Livingstone, Edinburgh (1999).

41.

Rollnick, S., Miller, W.R., Butler, C.: Motivational interviewing in health care: helping patients change behavior. Guilford Press, New York (2008).

42.

Hubley, J., Copeman, J., Woodall, J.: Practical health promotion. Polity Press, Cambridge (2013).

Laverack, G.: Health promotion practice: building empowered communities. Open University Press, Maidenhead (2007).

44.

Macdowall, W., Bonell, C., Davies, M.: Health promotion practice. Open University Press, Maidenhead (2006).

45.

Walker, R., Whittlesea, C.: Clinical pharmacy and therapeutics. Churchill Livingstone, Edinburgh (2012).

46.

Kumar, P.J., Clark, M.L.: Kumar & Clark's clinical medicine. Saunders Elsevier, Edinburgh (2012).

47.

Greene, R.J., Harris, N.D.: Pathology and therapeutics for pharmacists: a basis for clinical pharmacy practice. Pharmaceutical Press, London (2008).

48.

Coeliac disease: recognition, assessment and management | Guidance and guidelines | NICE.

49.

Chronic obstructive pulmonary disease, http://cks.nice.org.uk/chronic-obstructive-pulmonary-disease.

CPPE - Centre for Pharmacy Postgraduate Education, https://www.cppe.ac.uk/.

51.

Royal Pharmaceutical Society (RPS), http://www.rpharms.com/home/home.asp.

52.

Heart failure - chronic, http://cks.nice.org.uk/heart-failure-chronic.

53.

Medicines Use Review and Prescription Intervention service, http://psnc.org.uk/wp-content/uploads/2013/06/MUR-service-spec-Aug-2013-changes_FINA L.pdf.

54.

Service specification - New Medicine Service (NMS), http://psnc.org.uk/wp-content/uploads/2013/06/NMS-service-spec-Aug-2013-changes_FINA L.pdf.

55.

Commissioners and healthcare professionals - Training videos, http://healthcheck.nhs.uk/commissioners and providers/training/training videos1/.

56.

NHS Health Check - NHS Choices, http://www.nhs.uk/Conditions/nhs-health-check/Pages/NHS-Health-Check.aspx.